<p>Genprex Inc. is currently facing a regulatory issue related to its continued listing on the Nasdaq Capital Market. The company previously received a notice from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1). Although Genprex has raised additional capital through recent offerings and believes it now meets the equity requirement, the final determination from the Nasdaq Hearings Panel is still pending. The company’s common stock remains at risk of delisting until the Panel confirms compliance with all applicable Nasdaq listing standards. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-038601), on December 23, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

GNPX

<p>Genprex Inc. faces uncertainty regarding its Nasdaq listing due to non-compliance with stockholders' equity requirements. Despite raising additional capital, the final decision from the Nasdaq Hearings Panel is pending. The company's stock risks delisting until compliance is confirmed.</p>

Genprex Faces Nasdaq Listing Uncertainty Over Stockholders' Equity Compliance